dc.contributor.author | Maen, Abdelrahim | |
dc.contributor.author | Gök Yavuz, Betül | |
dc.contributor.author | Mohamed, Yehia I. | |
dc.contributor.author | Esmail, Abdullah | |
dc.contributor.author | Lu, Jianming | |
dc.contributor.author | Mohamed, Amr | |
dc.contributor.author | Azmi, Asfar S. | |
dc.contributor.author | Kaseb, Mohamed | |
dc.contributor.author | Kasseb, Osama | |
dc.contributor.author | Li, Dan | |
dc.contributor.author | Gocio, Michelle | |
dc.contributor.author | Koçak, Mehmet | |
dc.contributor.author | Selim, Abdelhafez | |
dc.contributor.author | Ma, Qing | |
dc.contributor.author | Kaseb, Ahmed O. | |
dc.date.accessioned | 2024-03-06T12:36:54Z | |
dc.date.available | 2024-03-06T12:36:54Z | |
dc.date.issued | 2024 | en_US |
dc.identifier.citation | Maen, A., Gök Yavuz, B., Mohamed, Y. I., Esmail, A., Lu, J., Mohamed, A. ... Kaseb, A. O. (2024). Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Frontiers in Pharmacology, 15. https://dx.doi.org/10.3389/fphar.2024.1291212 | en_US |
dc.identifier.issn | 1663-9812 | |
dc.identifier.uri | https://dx.doi.org/10.3389/fphar.2024.1291212 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12340 | |
dc.description.abstract | Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Frontiers Media Sa | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | COVID-19 | en_US |
dc.subject | Thymoquinone TQ | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | COVID-19 and Anti-Viral Agents | en_US |
dc.subject | TQ Formula | en_US |
dc.subject | Fatty Acids | en_US |
dc.title | Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Frontiers in Pharmacology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik ve Tıp Bilişimi Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-3386-1734 | en_US |
dc.identifier.volume | 15 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3389/fphar.2024.1291212 | en_US |
dc.institutionauthor | Koçak, Mehmet | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001164632500001 | en_US |
dc.identifier.scopus | 2-s2.0-85185316688 | en_US |
dc.identifier.pmid | 38379905 | en_US |
dc.identifier.scopusquality | Q1 | en_US |